Description
- Gout negatively affects quality of life due to excruciating pain, chronic arthropathy and associated comorbidities (renal, cardiovascular, metabolic syndrome and osteoarthritis).
- Gout is significantly under-treated, with hypouricemic treatments (the cornerstone of appropriate gout management) either frequently not used, or under-dosed if used.
Indication
- Management of patients with signs and symptoms of primary or secondary gout (acute attack, tophus, joint destruction, uric acid lithiasis and/or nephropathy).
- For the treatment of primary or secondary uric acid nephropathy, with or without signs or symptoms of gout.
- As prophylaxis, to prevent tissue urate deposits or kidney stones in patients with leukemia, lymphoma or other malignancies receiving antineoplastic therapy (radiotherapy or cytotoxic drugs).
- Treatment and prophylaxis of acute uratic nephropathy and resulting renal failure in patients with neoplastic disease who are particularly susceptible to hyperuricemia and uric acid stone formation (particularly after radiotherapy or use of antineoplastic drugs).
- Prevention of the onset and recurrence of uric acid stones or gravelly and calcific renal lithiasis in patients with hyperuricemia and/or hyperuricosuria.
